JPRN-jRCT2080221110UnknownPhase 2
Phase II/III induction study of AJG501 in patients with active ulcerative colitis
Ajinomoto Pharmaceuticals Co., Ltd.0 sitesStarted: May 25, 2010Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 16age old to <= 64age old (—)
- Sex
- All
Inclusion Criteria
- •Baseline Revised Sutherland DAI score of 4-8 including abnormal rectal bleeding score
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Unknown
Phase 3
Phase III study of AJG511 in patients with active ulcerative colitisulcerative colitisJPRN-jRCT2080222653EA Pharma Co.,Ltd.120
Unknown
Phase 2
Phase II study of AJG511 in patients with active ulcerative colitislcerative colitisJPRN-jRCT2080222245Ajinomoto Pharmaceuticals Co., Ltd.
Unknown
Phase 3
Phase III Clinical Study of AJG522 : Studies of safety and efficacy of AJG522 as a colon preparation agent for colonoscopy - Comparative study with MGV-5Patients scheduled for colonoscopyJPRN-jRCT2080221438Ajinomoto Pharmaceuticals Co., Ltd.
Unknown
Phase 2
Phase II/III maintenance study of AJG501 in patients with ulcerative colitislcerative colitisJPRN-jRCT2080221044Ajinomoto Pharmaceuticals Co., Ltd.
Unknown
Phase 2
Phase-IIa Study of AJM300 in Patients with Active Ulcerative Colitislcerative ColitisJPRN-jRCT2080222244Ajinomoto Pharmaceuticals Co., Ltd.